A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice.
If you are looking for guidance based on this study's results: IFM_05-May 2022
The (often referred to simply as the IFM-05 study) focused on using lenalidomide as a maintenance treatment.
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. A significant number of patients (roughly 27%) had
The study demonstrated a clear overall survival benefit for patients receiving maintenance therapy compared to a placebo.
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations If you are looking for guidance based on
Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI
